“We all knew that if we planned to get this investigational Janssen COVID-19 vaccine candidate out quickly, we would have to help get done in months what normally takes years.” “Vaccine development and production typically takes five to seven years, but our R&D and supply chain teams didn’t have the luxury of time,” says Paul Lefebvre, Vice President, Strategic Initiatives, COVID-19 Vaccine Supply Chain, Janssen Pharmaceutical Companies of Johnson & Johnson. The company also announced a goal of making it available for potential emergency use in early 2021-and to supply doses for emergency pandemic use on a not-for-profit basis. If you're curious to see what this teamwork is like in action, here's a month-by-month look at our vaccine’s journey from single cells in the laboratory to vials stocked in a warehouse.Īs soon as news of SARS-CoV-2-the virus that causes COVID-19-hit early last year, Johnson & Johnson began to research potential investigational vaccine candidates in partnership with the Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School.īased on this work, scientists were able to identify a lead investigational Janssen COVID-19 vaccine candidate in March. “It’s a testament to the inspiring teamwork exemplified at our company,” Colarusso says. For well over a century, the company has played a leading role in helping to address epidemics and pandemics through innovation, dating as far back as the Spanish flu outbreak of 1918, when it began mass-producing epidemic masks. Indeed, Johnson & Johnson is built for times like these. This crucial work and such unprecedented partnerships speak to Our Credo, the company's guiding mission statement, which states that Johnson & Johnson's first responsibility is to the patients, doctors and nurses, mothers and fathers and all others who use the company's products. Through the agreement, Merck will use its facilities to produce drug substance, as well as formulate and fill vials of Johnson & Johnson’s vaccine. government that Johnson & Johnson will partner with Merck to make its Janssen COVID-19 Vaccine. "So we get to build on what we already have, which really helps us with transportation and distribution without the need for special temperatures.”Īdd to that an announcement today from the U.S. “We have standard cold chain technologies that we’ve been using for more than 30 years to distribute other medications," says Remo Colarusso Remo Colarusso, Vice President, Janssen Supply Chain, LLC at Johnson & Johnson, Vice President, Janssen Supply Chain, LLC, Johnson & Johnson. 8 Things to Know About Johnson & Johnson's Janssen COVID-19 Vaccine
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |